Home Page
   HEMOLYTIK: A Database of Hemolytic and Non-hemolytic Peptides

Detailed description page of Hemolytik

This page displays user query in tabular form.

3260 details
Primary information
Hemolytik ID3260
PMID23415044
YEAR2013
SEQUENCEFLHFLHHLF
LENGTH9
NAMEH3
C-ter ModificationFree
N-ter ModificationFree
Linear/CyclicLinear
StereochemistryL
Modified ResiduesNone
FUNCTIONAntiviral
ACTIVITYHC50 =416.4μg/ml
RBCs SOURCEHuman
Secondary information
PropertiesPhysico-Chemical details
STRUCTURE
Natural StructureFinal Structure
DSSP statesCCCCCCCCC
SMILESN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
External Links
PDB exactPDB partialSP exactSP partialTrEMBL exactTrEMBL partialIEDB exactIEDB partial
NA NA NA NA NA NA NA NA
Reference Informaiton
ARTICLEDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.
AUTHORSHong W,Zhang R,Di Z,He Y,Zhao Z,Hu J,Wu Y,Li W
JOURNALBiomaterials. 2013 Apr;34(13):3511-22. doi: 10.1016/j.biomaterials.2013.01.075. Epub 2013 Feb 13.